29 February 2016
RAC/A/36/2016

Final Agenda
36th meeting of the Committee for Risk Assessment

29 February - 10 March 2016

ECHA Conference Centre (Annankatu 18, Helsinki)

Monday 29 February starts at 14.00
Friday 4 March breaks at 13.00
Tuesday 8 March resumes at 14.00
Thursday 10 March ends at 13.00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/36/2016
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

a) Report on RAC 35 action points, written procedures and update on other ECHA bodies

RAC/36/2016/01

RAC/36/2016/02
Room document

For information

b) Feedback from the Commission on RAC opinions

For information and discussion

c) RAC workplan for all processes

For information

Item 5 – Requests under Article 77 (3)(c)

No requests.

Item 6 – Requests under Article 95 (3)

a) 1-methyl-2-pyrrolidone (NMP)

RAC/36/2016/03
Restricted document
For discussion/agreement

b) OEL-DNEL methodology request

For information

Item 7 – Harmonised classification and labelling (CLH)

7.1 General CLH issues

a) Update on CLP activities

For information

7.2 CLH dossiers

A. Hazard classes for agreement without plenary debate (fast-track)

- Amisulbrom (ISO): physical hazards, health hazards (Acute toxicity - all routes of exposure, Skin corrosion / irritation, Respiratory or skin sensitisation, STOT SE, STOT RE, Germ cell mutagenicity), aquatic hazards
- Chlorocresol: health hazards (Acute toxicity - all routes of exposure, STOT SE), aquatic hazards
- Flutianil (ISO): physical hazards, health hazards (Acute toxicity – all routes of exposure, STOT SE, Skin corrosion / irritation, Serious eye damage / eye irritation, Skin sensitisation), aquatic hazards
- Pyroxsulam (ISO): physical hazards, health hazards (Acute toxicity – all routes of exposure, Skin corrosion / irritation, Serious eye damage / eye irritation, Respiratory or skin sensitisation, STOT SE, STOT RE, Germ cell mutagenicity, Toxicity to reproduction, Aspiration hazard), aquatic hazards
- Epsilon-metofluthrin: physical hazards, health hazards (Acute toxicity – dermal an inhalation routes of exposure, Skin corrosion / irritation, Serious eye damage / eye irritation, Respiratory or skin sensitisation, Germ cell mutagenicity, Toxicity to reproduction, Aspiration hazard, aquatic hazards
- 2-methylisothiazol-3(2*H*)-one (MIT): physical hazards, health hazards (acute toxicity via oral route of exposure, respiratory sensitisation, STOT RE, carcinogenicity, germ cell mutagenicity, toxicity to reproduction)

- Reaction mass of 5-chloro-2-methyl-2*H*-isothiazol-3-one and 2-methyl-2*H*-isothiazol-3-one (3:1) (C(M)IT/MIT): physical hazards, health hazards (Acute toxicity – oral route of exposure, STOT SE, EUH071), aquatic hazards

B. Hazard classes for agreement with plenary debate

a) Amisulbrom (ISO)
b) Chlorocresol
c) Flutianil (ISO)
d) Pyroxsulam (ISO)
e) Isoeugenol
f) Epsilon-metofluthrin
g) 2-methylisothiazol-3(2*H*)-one (MIT)
h) Reaction mass of 5-chloro-2-methyl-2*H*-isothiazol-3-one and 2-methyl-2*H*-isothiazol-3-one (3:1) (C(M)IT/MIT)
i) Salicylic acid

For discussion and adoption

7.3 Appointment of RAC (co-)rapporteurs for CLH dossiers

RAC/36/2016/04
Restricted room document
For agreement

Item 8 – Restrictions

8.1 General restriction issues

a) Carcinogenicity dose-response relationship development for cobalt salts

RAC/36/2016/05
For discussion

b) Report from the Restrictions workshop held in Brussels on 19-20 January 2016

For information

8.2 Restriction Annex XV dossiers

a) Opinion development

1) D4/D5 – revised draft opinion

For adoption

8.3 Appointment of (co-)rapporteurs for restriction dossiers

For information

Item 9 – Authorisation

9.1 General authorisation issues

a) Capacity building

1. DNEL setting for the reprotoxic properties of 1-bromopropane
2. DNEL setting for the reprotoxic properties of diisopentylphthalate (DIPP)
3. Carcinogenicity dose-response relationship development for Al-RCF and Zr-RCF

For discussion

b) Update on incoming/future applications for authorisation

For information

9.2 Authorisation applications

a) Outcome of the conformity check and presentation of the key issues

1. Sodium dichromate-Brenntag (SD_Brenntag)
2. Potassium dichromate-Brenntag (PD_Brenntag)
3. Dichromium tris(chromate)-Henkel (DtC_Henkel)
4. Strontium chromate-Akzo Nobel (SC_Akzo)
5. Potassium hydroxyoctaoxodizincatedichromate-PPG (PH_PPG)
6. Sodium dichromate-Akzo Nobel (SD_Akzo)
7. Sodium dichromate-Solvay (SD_Solvay)
8. Sodium dichromate-Arkema (SD_Arkema)
9. Sodium dichromate-Ercros (SD_Ercros)
10. Sodium dichromate-Electroquimica (SD_ELECTRQUIMICA)
11. Sodium dichromate-Kemira (SD_Kemira)
12. Sodium dichromate-Caffaro Brescia (SD_Caffaro)
13. Chromium trioxide-Federal-Mogul Friedberg (CT_Friedberg)
14. Chromium trioxide-Federal-Mogul Valvetrain (CT_Valvetrain)
15. Chromium trioxide-Federal-Mogul Burscheid (CT_Burscheid)
16. Chromic acid-Bosch (CA_Bosch)
17. Chromium trioxide-Circuit Foil Luxembourg (CT_Circuit)
18. Arsenic acid-Circuit Foil Luxembourg (AsA_Circuit)
19. Chromium trioxide and dichromium tris(chromate)-Nexter Mechanics (CT_DtC_Nexter)
20. Chromium trioxide-Praxair (CT_Praxair)
21. Potassium dichromate-Sofradir (PD_Sofradir)
22. Sodium dichromate-Lanxess (SD_Lanxess)
23. Ammonium dichromate-Micrometal (AD_Micrometal)
24. Chromium trioxide-Cromomed (CT_Cromomed)

25. Chromium trioxide-Rimex Metals (CT_Rimex)
26. EDC-BASF (EDC_BASF)
27. Diglyme-Novartis (Diglyme_Novartis)

For discussion and agreement

b) First version of the draft opinion:

1. Chromium trioxide-Kromatek

Use 1: Use of chromium trioxide in Cr(VI) based functional plating

2. Chromium trioxide-Grohe

Use 1: The use of chromium trioxide for electroplating of different types of substrates with the purpose of creating a long-lasting, high durability surface with a shiny or matte look (also called 'functional plating with decorative character')
Use 2: The use of Chromium Trioxide for pre-treatment step in the electroplating process

For discussion and agreement

c) Second version of the draft opinion:

1. Six uses of chromium trioxide submitted by *LANXESS Deutschland GmbH* on behalf of a group of companies (**Chromium trioxide 1**):

Use 1: Formulation of mixtures

For discussion and agreement

Use 2: Functional chrome plating
Use 3: Functional chrome plating with decorative character
Use 4: Surface treatment for applications in the aeronautics and aerospace industries, unrelated to Functional chrome plating or Functional plating with decorative character
Use 5: Surface treatment (except ETP) for applications in various industry sectors namely architectural, automotive, metal manufacturing and finishing, and general engineering

For discussion

Use 6: Passivation of tin-plated steel (ETP)

For discussion and agreement

9.3 Appointment of (co-)rapporteurs for authorisation applications

RAC/36/2016/06
Restricted room document
For agreement

Item 10 – AOB

Item 11 – Action points and main conclusions of RAC-36

Table with Conclusions and Action points from RAC-36

For adoption